Trial Profile
Combination Therapy Using Mycophenylate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Mycophenolate mofetil
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 23 Mar 2013 Results with focus on efficacy and tolerability presented at the 65th Annual Meeting of the American Academy of Neurology.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2011 Planned End Date changed from 1 Dec 2010 to 1 May 2012 as reported by ClinicalTrials.gov.